Reboxetine may cause amenorrhea in female patients

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue 3, 2006, Pages 223-225

  Yalug, Irem ^a,c   Tural, U ^a   Unsalan, N ^b   Tufan, A E ^a   Ozten, E ^a  

^a Public Health   (Turkey)

^b MALTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Amenorrhea; Depression; Noradrenaline; Prolactin; Reboxetine

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; REBOXETINE;

ADULT; AMENORRHEA; ANAMNESIS; ANXIETY DISORDER; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; FEMALE; HUMAN; LABORATORY TEST; MAJOR DEPRESSION; MENSTRUAL CYCLE; MENSTRUATION; PRIORITY JOURNAL;

EID: 33748463940     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600633071     Document Type: Article

References (10)

1. Kadhe NG, Chillar AJ, Deshmukh YA. Reboxetine: A novel antidepressant. J Postgrad Med 2003;49:373-5.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Washington, DC: The American Psychiatric Association; 1994.
3. Schule C, Baghai T, Schmidbauer S, et al. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 2004;29:185-200.
4. Schule C, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004;79:54-62.
5. Moeller O, Hetzel G, Michael N, et al. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram. Neuropsychobiology 2005;51:67-71.
6. Cleare AJ, Murray RM, O'Keane V. Do noradrenergic reuptake inhibitors affect serotonergic function in depression? Psychopharmacology (Berlin) 1997;134:406-10.
7. Lin KC, Lee JN, Jong SB. Assessment of hypothalamicpituitary function by hormonal pulsatility, gonadotropin-releasing hormone and thyrotropin-releasing hormone testing in women with euprolactinemic secondary amenorrhea. Kaohsiung J Med Sci 1998;14:698-705.
8. Harlow BL, Wise LA, Otto MW, et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2003;1:29-36.
9. Clark DWJ, Correa-Nunes A-M, Edwards IR. Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome). Eur J Clin Pharmacol 2003;59:261-2.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.